# Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

> **NCT06731803** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 36 (estimated)

## Conditions studied

- Esophagogastric Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab deruxtecan + 5FU/LV
- **DRUG:** Trastuzumab deruxtecan + FLO

## Key facts

- **NCT ID:** NCT06731803
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731803, "Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06731803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*